Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS

Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS

Source: 
Pharmaceutical Business Review
snippet: 


Takeda Pharmaceutical has secured a breakthrough therapy designation from the US Food and Drug Administration (FDA) for its investigational drug pevonedistat to treat patients with higher-risk myelodysplastic syndromes (HR-MDS).